Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.
Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.
复制标题
DOI:
10.1016/j.nbd.2010.10.015
复制
发表时间:
2011-02
影响因子:
6.1
通讯作者:
Lynch, Gary
中科院分区:
文献类型:
--
作者:
Simmons, Danielle A.;Mehta, Rishi A.;Lauterborn, Julie C.;Gall, Christine M.;Lynch, Gary
Daily, systemic injections of a positive AMPA-type glutamate receptor modulator (ampakine) have been shown to reduce synaptic plasticity defects in rodent models of aging and early-stage Huntington’s Disease (HD). Here we report that long-term ampakine treatment markedly slows the progression of striatal neuropathology and locomotor dysfunction in the R6/2 HD mouse model. Remarkably, these effects were produced by an ampakine, CX929, with a short half-life. Injected once daily for 4–7 weeks, the compound increased protein levels of brain-derived neurotrophic factor (BDNF) in neocortex and striatum of R6/2 but not wild-type mice. Moreover, ampakine treatments prevented the decrease in total striatal area, blocked the loss of striatal DARPP-32 immunoreactivity and reduced the area of intranuclear huntingtin aggregates in R6/2 striatum by 36%. The CX929 treatments also markedly improved motor performance of R6/2 mice on several measures (rotarod, vertical pole descent) but did not influence body weight or lifespan. These findings describe a minimally invasive, pharmacologically plausible strategy for treatment of HD and, potentially, other neuropathological diseases.
登录
查看更多内容
影响因子:
3.3
作者:
Hickey MA;Kosmalska A;Enayati J;Cohen R;Zeitlin S;Levine MS;Chesselet MF
通讯作者:
Chesselet MF
影响因子:
5.3
作者:
Canals, JM;Pineda, JR;Alberch, J
通讯作者:
Alberch, J
影响因子:
4.7
作者:
Chou, SY;Lee, YC;Chern, YJ
通讯作者:
Chern, YJ
影响因子:
4.8
作者:
Bogush, Alexey;Pedrini, Steve;Ehrlich, Michelle E.
通讯作者:
Ehrlich, Michelle E.
影响因子:
4.7
作者:
Deltheil, T.;Guiard, B. P.;Gardier, A. M.
通讯作者:
Gardier, A. M.